BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Revolution Medicines readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Revolution Medicines's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05379985-2216@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT05379985)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RMC-6236 in Patients With Advanced Solid Tumors Harbor
 ing Specific Mutations in RAS\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05379985
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-1997@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elironrasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881784-2216@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT06881784)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSC
 LC (RASolve 301)\nEstimated primary completion: 1 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06881784
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-2216@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07491445)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib and Daraxonrasib + GnP as First-line 
 Treatment in Patients With Metastatic Pancreatic Adenocarcinoma\nEstimated
  primary completion: April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2216@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Pancreatic Ductal Adenoca
 rcinoma.\nStudy: Study of RAS(ON) Inhibitors in Patients With Gastrointest
 inal Solid Tumors\nEstimated primary completion: 30 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06445062
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-1997@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Ther
 apy in Participants With Advanced KRAS G12C Mutant Solid Tumors\nEstimated
  primary completion: December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elironrasib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621718-2827@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07621718)
DESCRIPTION:Zoldonrasib\, phase 3\, Pancreatic Cancer.\nStudy: Study of Zol
 donrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigat
 or's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancre
 atic Adenocarcinoma ( RASolute 305 )\nEstimated primary completion: 30 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zoldonras
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7621718
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805954-2216@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07805954)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236
 ) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metasta
 tic KRAS G12D-Mutated Pancreatic Adenocarcinoma\nEstimated primary complet
 ion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 xonrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07805954
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-1997@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/elironrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252232-2216@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290510
DTEND;VALUE=DATE:20290511
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07252232)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib (RMC-6236) in Patients With Resected 
 Pancreatic Ductal Adenocarcinoma (PDAC)\nEstimated primary completion: 10 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 252232
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07777822-2827@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07777822)
DESCRIPTION:Zoldonrasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Z
 oldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mut
 ated NSCLC\nEstimated primary completion: October 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07777822
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
